07:54 AM EDT, 09/24/2025 (MT Newswires) -- Acadia Pharmaceuticals ( ACAD ) said Wednesday its ACP-101, or intranasal carbetocin, therapy candidate for patients with hyperphagia in Prader-Willi syndrome did not meet its primary efficacy endpoint in a phase 3 trial.

The therapy candidate failed to demonstrate a 'statistically significant improvement over placebo' from baseline to week 12.

Acadia plans to share a summary of the trial's data "in the future" but said it does not plan to investigate intranasal carbetocin any further.

Shares of Acadia Pharmaceuticals ( ACAD ) were down more than 11% in recent Wednesday premarket activity.